user Sign In

QYResearch Account

Manage your Account and Access Personalized Content.

Sign in

Create Account with us

Manage your Account and Access Personalized Content.

Sign Up
       
  
×

Global Levofloxacin Growth Potential Report 2019

Published Date: 2019-02-11   |   Pages: 97   |   Tables: 105   | Report Id: 991487   | Hits: 5 |   Pharma & Healthcare



Levofloxacin, sold under the trade names Levaquin among others, is an antibiotic. It is used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis, meningitis, or pelvic inflammatory disease. It is available by mouth, intravenously, and in eye drop form.

Factors such as increasing incidences of bacterial infections such as pneumonia & urinary tract infections (UTI) and broad spectrum efficacy drive the market growth.

However, side effects associated with levofloxacin such as tendon inflammation, psychosis, and seizures restrain the market growth.

Furthermore, rising geriatric population and growing initiatives by the government to spread awareness about severe infections are expected to further drive the market growth.

The global Levofloxacin market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.

This report focuses on Levofloxacin volume and value at global level, regional level and company level. From a global perspective, this report represents overall Levofloxacin market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.

At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.

The following manufacturers are covered:

Alna Biotech Private

Allenge India Pharma

Bestochem

Divine Savior Healthcare

Glenmark Pharmaceuticals

Pax Healthcare

Aden Healthcare

Lupin Pharmaceuticals

Dr. Reddys Laboratories

Zydus Cadila

Segment by Regions

North America

Europe

China

Japan

Segment by Type

250 mg

500 mg

750 mg

Segment by Application

Pneumonia

Skin Infection

Kidney Infection

Bladder Infection

Others

Licenses Type

Only one user can access the report
Multiple users can access the report

Why QYR

 Fastest report delivery service
 More than 10 years of vast experience
 Operational for 24 * 7 & 365 days
 In-depth and comprehensive analysis
 Excellent after sales support
 Owns large database

Need Help ?

QYR Clients

More Clients...